Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-05
2007-06-05
Lambkin, Deborah C. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S380000, C514S369000, C514S342000, C514S341000, C514S340000, C514S314000, C548S317100, C548S226000, C548S183000, C546S274400, C546S271400, C546S270400, C544S135000
Reexamination Certificate
active
11210403
ABSTRACT:
The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4824833 (1989-04-01), Iijima et al.
patent: 4897393 (1990-01-01), Iijima et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 7019223 (2006-03-01), Rumsey et al.
patent: 7026334 (2006-04-01), Takemoto et al.
patent: 7105552 (2006-09-01), Nag et al.
patent: 7105556 (2006-09-01), Cheng et al.
patent: 7115640 (2006-10-01), Martin et al.
patent: 2002/0143182 (2002-10-01), Pfahl et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0144329 (2003-07-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 2005/0014767 (2005-01-01), Pfahl et al.
patent: 2005/0038098 (2005-02-01), Tachdjian et al.
patent: 2005/0070581 (2005-03-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (1998-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/66167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: WO 02/080935 (2002-10-01), None
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Re., 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc., 121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Barclay et al., “ortho-Diquaternary aromatic compounds. III. Synthesis and reactions of polyalkyltetralones and derivatives,”Canadian Journal of Chemistry, 48(17):2763-2775 (1970).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis, 829-830 (1981).
Blondet et al., “Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-1,2,3,4-Tetrahydro-2-Quinolinone,”Organic Preparation and Procedures Int., 25(2):223-228 (1993).
Bozdag, CA, 133:309865, Abstract of Arzneimittel-Forschung, 50(7):626-630 (2000).
Bozdag, CA, 133:237715, Abstract of Arzneimittel-Forschung, 50(6):539-543 (2000).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,”J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci., 87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNF Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Cacchi et al., “Palladium-Catalyzed Triethylammonium Formate Reduction of Aryl Triflates. A Selective Method for the Deoxygenation of Phenols,”Tetrahedron Letters, 27(45):5541-5544 (1986).
Cantello et al., “A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-dionesviaRegiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione,”Synlett, 263-264 (1997).
Cantello et al., “The Synthesis of BRL 49653—A Novel and Potent Antihyperglycaemic Agent,”Bioorganic&Medicinal Chemistry Letters, 4:1181-1184 (1994).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters, 39:2933-2936 (1998).
Chang et al., “The Upjohn Colony of KkayMice: A Model for Obese Type II Diabetes,”Elsevier Science Publishers B. V., Biomedical Division, Diabetes, pp. 466-470 (1986).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem., 38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,”Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem., 41:5055-5069 (1998).
Coleman, “Diabetes-Obesity Syndromes in Mice,”Diabetes, 31(1):1-6 (Apr. 1982).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl-and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Dawson et al., “Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity,”J. Med. Chemistry, 38:3368-3383 (1995).
Dawson et al., “The Synthetic Chemistry of Retinoids,”Biology, Chemistry, and Medicine, 2ndEdition, Raven Press, Ltd., New York (1994).
Ebisawa et al., “Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity,”Biol. Pharma. Bull., 21(5):547-549 (1998).
Ertan, CA, 126:293290, Abstract of Acta pharmaceutica Turcica, 39(1):33-37 (1997).
Evans et al., “Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetrahedron Letters, 39:2937-2940 (1998).
Farahat et al., “Cytokine Epression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis,”Ann. Rheum. Dis., 52:870-875 (1993).
Faul et al., “Synthesis of Novel Retinoid X Receptor-Selective Retinoids,”J. Org. Chem., 66:5772-5782 (2001).
Ferrell, “Tripping the Switch
Al-Shamma Hussien A.
Fanjul Andrea
Pfahl Magnus
Pleynet David P. M.
Spruce Lyle W.
Incyte San Diego Inc.
Lambkin Deborah C.
Needle & Rosenberg P.C.
Ortho -McNeil Pharmaceutical, Inc.
LandOfFree
Substituted heterocycles for the treatment of diabetes and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocycles for the treatment of diabetes and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocycles for the treatment of diabetes and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833222